Export 5 results:
Author Title Type [ Year(Desc)]
Filters: Author is Abbink, Peter  [Clear All Filters]
2012
D. H. Barouch, Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., M Iampietro, J., SanMiguel, A., Seaman, M. S., Ferrari, G., Forthal, D. N., Ourmanov, I., Hirsch, V. M., Carville, A., Mansfield, K. G., Stablein, D., Pau, M. G., Schuitemaker, H., Sadoff, J. C., Billings, E. A., Rao, M., Robb, M. L., Kim, J. H., Marovich, M. A., Goudsmit, J., and Michael, N. L., “Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.”, Nature, vol. 482, no. 7383, pp. 89-93, 2012.
2013
L. R. Baden, Walsh, S. R., Seaman, M. S., Tucker, R. P., Krause, K. H., Patel, A., Johnson, J. A., Kleinjan, J., Yanosick, K. E., Perry, J., Zablowsky, E., Abbink, P., Peter, L., M Iampietro, J., Cheung, A., Pau, M. G., Weijtens, M., Goudsmit, J., Swann, E., Wolff, M., Loblein, H., Dolin, R., and Barouch, D. H., “First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).”, J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.
2014
L. R. Baden, Walsh, S. R., Seaman, M. S., Johnson, J. A., Tucker, R. P., Kleinjan, J. A., Gothing, J. A., Engelson, B. A., Carey, B. R., Oza, A., Bajimaya, S., Peter, L., Bleckwehl, C., Abbink, P., Pau, M. G., Weijtens, M., Kunchai, M., Swann, E. M., Wolff, M., Dolin, R., and Barouch, D. H., “First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).”, J Infect Dis, vol. 210, no. 7, pp. 1052-61, 2014.
2015
L. R. Baden, Liu, J., Li, H., Johnson, J. A., Walsh, S. R., Kleinjan, J. A., Engelson, B. A., Peter, L., Abbink, P., Milner, D. A., Golden, K. L., Viani, K. L., Stachler, M. D., Chen, B. J., Pau, M. G., Weijtens, M., Carey, B. R., Miller, C. A., Swann, E. M., Wolff, M., Loblein, H., Seaman, M. S., Dolin, R., and Barouch, D. H., “Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.”, J Infect Dis, vol. 211, no. 4, pp. 518-28, 2015.
2018
K. Modjarrad, Lin, L., George, S. L., Stephenson, K. E., Eckels, K. H., De La Barrera, R. A., Jarman, R. G., Sondergaard, E., Tennant, J., Ansel, J. L., Mills, K., Koren, M., Robb, M. L., Barrett, J., Thompson, J., Kosel, A. E., Dawson, P., Hale, A., C Tan, S., Walsh, S. R., Meyer, K. E., Brien, J., Crowell, T. A., Blazevic, A., Mosby, K., Larocca, R. A., Abbink, P., Boyd, M., Bricault, C. A., Seaman, M. S., Basil, A., Walsh, M., Tonwe, V., Hoft, D. F., Thomas, S. J., Barouch, D. H., and Michael, N. L., “Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.”, Lancet, vol. 391, no. 10120, pp. 563-571, 2018.